Jeske Smink
Head of Drug Substance, Silence Therapeutics plc
Jeske is a biologist with over 18 years’ experience in the biotech industry and academic research. She has expertise in CMC aspects in different areas, including cell therapies, biologics and siRNA’s. After 7 years in academic research focussing on molecular mechanisms in bone development and diseases she moved to co.don AG and became Head of Scientific Affairs. Here her work focused on preclinical development and quality aspects of cartilage cell transplants. Following, she joined ProBioGen as CMC project leader, where she was overseeing customer projects, focusing on process development, scale-up and large scale GMP manufacturing of biologics. In 2020, Jeske joined Silence Therapeutics as Head of Drug Substance responsible for CMC development, including process and analytical development, scale-up and clinical product manufacturing of siRNA compounds.
